Use of modified vasoactive intestinal peptides in the treatment of hypertension
作者： Lynne M. Georgopoulos , Susan Arnold
DOI:
关键词: Pharmacology 、 Preference 、 Vasoactive 、 Concomitant 、 Blood pressure control 、 Endocrinology 、 Internal medicine 、 Medicine
摘要: The present invention is based on the discovery that a VIP having binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful treatment and/or amelioration of hypertension are provided.
lens.org 参考文章(158)
Rosa Perez Gomariz, Mario Delgado Mora, Javier Leceta Martinez, Carmen Martinez Mora, Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists ,(2002)
Homayoun Sadeghi, Biologically active proteins activatable by peptidase ,(2009)
Sudhir Paul, Yasuko Noda, Israel Rubinstein, Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide ,(1995)
Louis Y. Korman, Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure ,(1992)
Darlene A. Dartt, Thimothy L. Kessler, Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion ,(1994)
Clark Pan, Steve Roczniak, Vpac1 selective antagonists and their pharmacological methods of use ,(2005)
Illana Gozes, Matityahu Fridkin, Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof ,(1995)
Dan W. Urry, Elastomeric composite material comprising a polypeptide ,(1981)